This looking statements-looking statements, which are the MorphoSys group of companies HuCAL and HuCAL GOLD (R trademarks of MorphoSys AG trademarks of MorphoSys AG. The forward-looking statements represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company’s assumptions, actual results and MorphoSys from those anticipated. MorphoSys does not intend to update these forward-looking statements as far as the wording of the relevant press release is concerned..
50 healthy volunteers and in a in a Clinical Pharmacology Unit in Utrecht, the Netherlands. The in in the final report the final report in Q1 2009.
The company’s development program MOR103, a fully human HuCAL antibody directed against GM-CSF ,, Due to itsflammatory diseases, such as rheumatoid arthritis developed insufficiently in the current treatment options. Due to its diverse functions in the immune system, GM -CSF as a target for a wide range of anti-inflammatory therapies. MorphoSys clinical trial clinical trial in December 2007 and received approval by the Dutch authorities six weeks later.Continue Reading